| Name | Cefepime |
| Description | Cefepime (BMY-28142) is a cephalosporin antibiotic with antimicrobial activity, induces neurotoxicity, inhibits both Gram-positive and Gram-negative, and can be used in the study of anaerobic bacteria. |
| In vivo | METHODS: Mice were given different doses of cisplatin (0, 10, 14, 18, 22, and 26 mg/kg) three days before intraperitoneal (ip) injection of 80 mg/kg cefepime to determine the dose of cisplatin that would not affect mouse survival and achieve human-like serum concentrations of cefepime.
RESULTS: The half-life of cefepime was significantly prolonged at cisplatin doses of 18 and 22 mg/kg. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (8.32 mM), Sonication is recommended.
DMSO : 120 mg/mL (249.71 mM), Sonication is recommended.
H2O : 80 mg/mL (166.47 mM), Sonication is recommended.
|
| Keywords | Cefepime | Antibiotic | Antibacterial |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | Kanamycin sulfate | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | BES |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | Antibiotics Library | Drug Repurposing Compound Library | Beta-Lactam Compound Library | Anti-Bacterial Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Human Metabolite Library | NMPA-Approved Drug Library |
United States
